The CDI values of 1.16 ± 0.1 (range, 1.04–1.39; Figure 1B) indicate an antagonistic interaction between gefitinib and cisplatin in the EGFR-mutant NSCLC PC9 cell lines. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.